Plaque Psoriasis

This review highlights phase 3 and long-term data on deucravacitinib therapy for patients with plaque psoriasis.

The investigators present pooled findings from the SUNSHINE and SUNRISE trials assessing secukinumab therapy for HS.

In this analysis, evidence which supports a shift in clinical practice using Chinese herbal medicine was explored for atopic dermatitis.

This cohort study suggests that patients with HS treated with adalimumab have an increased risk of infection compared to those with psoriasis.

A study reveals that upadacitinib dose adjustments in atopic dermatitis enhance treatment personalization.

This analysis suggests that GLP-1 RAs provide promise for those with HS and obesity and potentially for such individuals without obesity via immunological impacts.

The G-EPOSS study demonstrated the long-term impacts of guselkumab on patients’ psoriasis symptoms, sexual impairment, and perceived stigmatization.

Findings highlight an association between psoriasis and risks of all-cause, cardiovascular, infection-related, and suicide mortality.

Recent interview- and survey-based research has quantified the extent to which GPP impacts patients, examining both symptoms and mental health outcomes.

This systematic review and meta-analysis found that biologic switching was shown to be safe and effective among patients with psoriasis.

This summary of dermatology news coverage from the month of August 2025 highlights some of the most notable stories in this medical subfield.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

News coverage from DERM 2025 in the field of psoriasis is highlighted in this post-conference summary.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.

This interview with Hamade highlights some of the most notable takeaways regarding deucravacitinib’s safety among patients with psoriasis.

This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

In this video, the last in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fifth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fourth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the third in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the second in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the first in a 6-part series, panelists discuss recent advancements in PsO management.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.